Revisiting cell and gene therapies in Huntington's disease

J Neurosci Res. 2021 Jul;99(7):1744-1762. doi: 10.1002/jnr.24845. Epub 2021 Apr 21.

Abstract

Neurodegenerative movement disorders, such as Huntington's disease (HD), share a progressive and relentless course with increasing motor disability, linked with neuropsychiatric impairment. These diseases exhibit diverse pathophysiological processes and are a topic of intense experimental and clinical research due to the lack of therapeutic options. Restorative therapies are promising approaches with the potential to restore brain circuits. However, there were less compelling results in the few clinical trials. In this review, we discuss cell replacement therapies applied to animal models and HD patients. We thoroughly describe the initial trials using fetal neural tissue transplantation and recent approaches based on alternative cell sources tested in several animal models. Stem cells were shown to generate the desired neuron phenotype and/or provide growth factors to the degenerating host cells. Besides, genetic approaches such as RNA interference and the CRISPR/Cas9 system have been studied in animal models and human-derived cells. New genetic manipulations have revealed the capability to control or counteract the effect of human gene mutations as described by the use of antisense oligonucleotides in a clinical trial. In HD, innovative strategies are at forefront of human testing and thus other brain genetic diseases may follow similar therapeutic strategies.

Keywords: cell replacing therapy; embryonic stem cells; fetal neural tissue; genome editing; induced pluripotent stem cells; neural stem cells.

Publication types

  • Review

MeSH terms

  • Animals
  • Cell- and Tissue-Based Therapy / methods*
  • Cell- and Tissue-Based Therapy / trends
  • Genetic Therapy / methods*
  • Genetic Therapy / trends
  • Humans
  • Huntington Disease / therapy*